Niagen Bioscience Inc
niagenbioscience.comWhat Do They Do?
Sells finished Tru Niagen dietary supplements to consumers and Niagen ingredients to consumer-product manufacturers and compounding facilities.
10-K for FY2025, filed Mar 4, 2026Through our consumer products segment, we provide finished dietary supplement products containing our proprietary ingredients, marketed…View ↗
Through our Ingredients segment, we develop and commercialize proprietary ingredient technologies, including food-grade Niagen® and…View ↗
Manufacturers of consumer products incorporate our food-grade Niagen® into dietary supplement and food products. U.S. FDA-registered 503B…View ↗
How Do They Make Money?
Consumers and commercial partners buy finished supplements and Niagen ingredients; product sales are counted when goods ship. Research-service sales are counted as the services are performed.
10-K for FY2025, filed Mar 4, 2026Through our consumer products segment, we provide finished dietary supplement products containing our proprietary ingredients, marketed…View ↗
Through our Ingredients segment, we develop and commercialize proprietary ingredient technologies, including food-grade Niagen® and…View ↗
Since 1999, we have provided research and quality-control products and services through our analytical reference standards and services…View ↗
Revenue Recognition: The Company recognizes sales and the related cost of sales when the performance obligations are satisfied. The…View ↗
-
10-K for FY2025, filed Mar 4, 2026
FY2025 revenue by reportable segment ↗
$129.4M
-
10-K for FY2025, filed Mar 4, 2026
$129.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Consumer Products segment
Sold outright
10-K for FY2025, filed Mar 4, 2026 |
75%
FY2022: 83%
|
Consumer Products segment, FY2025
$97.7M Sources
|
Sold outright |
|
Ingredients segment
Sold outright
10-K for FY2025, filed Mar 4, 2026 |
22%
FY2022: 12%
|
Ingredients segment, FY2025
$28.7M Sources
|
Sold outright |
|
Analytical Reference Standards and Services segment
|
2.4%
FY2022: 4.5%
|
Analytical Reference Standards and Services segment, FY2025
$3.1M Sources
|
Who Are Their Customers?
Consumers buy Tru Niagen through the company’s online store, marketplaces, retailers and authorized healthcare practitioners; international partners sell through stores and online channels. Commercial partners buy ingredients for consumer products or compounding.
10-K for FY2025, filed Mar 4, 2026In the United States, we distribute Tru Niagen® products directly to consumers through our proprietary e-commerce platform TruNiagen.com…View ↗
In Canada, we distribute Tru Niagen® products directly to consumers through our proprietary e-commerce platform. Internationally, we…View ↗
Our ingredients segment is primarily supported through strategic partnerships, as we do not currently offer our ingredient products…View ↗
Food-grade Niagen® is sold to manufacturers of consumer products, which incorporate the ingredient into dietary supplement and food…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 13 cents of every revenue dollar as net income in FY2025.
10-K for FY2025, filed Mar 4, 2026
How Are They Changing?
10-Q for Q2 FY2026, filed Aug 4, 2026
Open tableView ↗
-
Aug 4, 2026
Launched a telehealth platform and pharmaceutical program
The 2026 outlook calls for e-commerce growth of 10% to 15%.
Sources
8-K, filed Aug 4, 2026
For the full year 2026, the Company expects the e-commerce business to grow 10% to 15% year-over-year. We continue to expect the remainder…View ↗
-
May 6, 2026
Sold analytical standards and services segment to LGC Standards
The divestiture was completed in an all-cash transaction.
Sources
8-K, filed May 6, 2026
In May 2026, the Company launched a clinician-directed telehealth platform under Niagen Plus, enabling eligible U.S. patients to access…View ↗
Growing. Revenue grew 92% in 4 years, from $67.4M in FY2021 to $129.4M in FY2025, about 18% a year.
Pharmaceutical-grade offerings
The earlier business description covered Niagen as a food ingredient; the latest adds pharmaceutical-grade Niagen supplied for compounding into intravenous and injectable products.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 4, 2026In 2013, we commercialized Niagen®, a proprietary form of NR, a novel form of vitamin B3. Data from numerous preclinical studies and human…View ↗
Analytical services segment sale
The earlier report described analytical reference standards and research services as an operating segment; the latest says the company sold the segment.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 4, 2026Analytical Reference Standards and Services SegmentView ↗
Loading...
